A further explanation is that many pediatric malignant brain tumors appear driven by epigenetic dysregulation such that tumors rarely harbor immediately actionable mutations, or display significant molecular heterogeneity making resistance to single agent targeted therapy anticipated, as is described for SHH-activated medulloblastoma [30]. This evidence concerns the gene SHH and medulloblastoma.